{"ATC Code":"N05CD05","Abbreviation":"","Aliases":["Songar","Clorazolam","Novidorm","Novodorm","Triazolamum","Triazolam civ","8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine","CCRIS 1932","U 33030","U-33030"],"Biological Half-Life":"1.5-5.5 hours","CAS":"28911-01-5","ChEBI":"CHEBI:9674","ChEMBL":"CHEMBL646","ChemicalClasses":["triazolobenzodiazepine"],"Chirality":"achiral","Classes":null,"Color/Form":"Tan crystals from 2-propanol","DEA no":2887,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Benzodiazepines","Drug Indication":"For the short-term treatment of insomnia.","Drug Warnings":"Pregnancy risk category: X  /CONTRAINDICATED IN PREGNANCY. Studies in animals or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or risk which clearly outweights any possible benefit to the patient./","DrugClasses":[],"DurationOfAction":"","EINECS":"249-307-3","EliminationHalfLife":"1.5 – 5.5 hours","Erowid Experience Reports":[{"Author":"Carson","Id":"100303","Title":"Relaxed and Happy to Lie Around"},{"Author":"Eraserhead","Id":"106711","Title":"Excellent for Sleep Assistance"},{"Author":"Fleming","Id":"116127","Title":"The Rock N Roll Benzo"},{"Author":"Frizzle","Id":"29726","Title":"I Feel...So...Chill"},{"Author":"Anonymous","Id":"41185","Title":"First Time with a Downer"},{"Author":"Vandall","Id":"48935","Title":"Faster Than the Rest"},{"Author":"Joe","Id":"53811","Title":"Peace In a Pill"},{"Author":"Anonymous","Id":"55222","Title":"One of the Best"},{"Author":"Molotov","Id":"64598","Title":"Altered Actions"},{"Author":"psychonaught","Id":"81963","Title":"Not So Deep but Comfortable and Dreamless Sleep"}],"European Community (EC) Number":"249-307-3","FDA Pharmacological Classification":"1HM943223R","HMDB ID":"HMDB0015034","HeavyAtomCount":23,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Benzodiazepines","IUPACName":"8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine","InChI":"InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3","InChIKey":"JOFWLTCLBGQGBO-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)","Melting Point":"233-235 °C","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e12\u003c/sub\u003eCl\u003csub\u003e2\u003c/sub\u003eN\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"343.2 g/mol","Pharmacodynamics":"A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites.","Physical Description":"Solid","PrevSalts":[],"PubChemId":5556,"Record Description":["Triazolam can cause developmental toxicity according to state or federal government labeling requirements.","Triazolam is a triazolobenzodiazepine. It has a role as a sedative.","Triazolam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.","Triazolam is a Benzodiazepine.","Triazolam is an orally available benzodiazepine used predominantly for therapy of insomnia. As with most benzodiazepines, triazolam has not been associated with serum aminotransferase or alkaline phosphatase elevations during therapy, and clinically apparent liver injury from triazolam has been reported but is very rare.","Triazolam is a triazolobenzodiazepinederivative with sedative-hypnotic property. Triazolam interacts directly with a specific site on the gamma-aminobutyric acid (GABA)-A-chloride-ionophore receptor complex located on the neuronal membrane. Binding causes allosteric modification of the receptor and modulation of its affinity for the inhibitory neurotransmitter GABA. This results in enhancement of synaptic actions of GABA and includes an increase in the frequency of chloride channel openings, increased chloride ion conductance, membrane hyperpolarization and ultimately synaptic inhibition and decreased neuronal excitability.","TRIAZOLAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for insomnia and has 5 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.","Triazolam is only found in individuals that have used or taken this drug. It is withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA\u003csub\u003eA\u003c/sub\u003e) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.","A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.","Triazolam can cause developmental toxicity according to state or federal government labeling requirements.","Triazolam is a triazolobenzodiazepine. It has a role as a sedative.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Triazolam","Name":"Triazolam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q412143","Name":"Triazolam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00897","Name":"Triazolam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5556","Name":"Triazolam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL646","Name":"Triazolam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9674","Name":"Triazolam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=28911-01-5","Name":"Triazolam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015034","Name":"Triazolam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00387","Name":"Triazolam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/1HM943223R","Name":"Triazolam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6046763","Name":"Triazolam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5556, Triazolam. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5556\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5556\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Triazolam. UNII: 1HM943223R. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1HM943223R\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/1HM943223R\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 26, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl","Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"act":"Single Convention on Narcotic Drugs 1961","gov":"United Nations","ref":[],"schedule":"Schedule IV narcotic"}],"Solubility":"Poorly soluble in water and soluble in alcohol.","StoreUNII":["1HM943223R"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="104.213mm" version="1.2" viewBox="0 0 82.985 104.213" width="82.985mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="105.0" stroke="none" width="83.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="42.507" x2="55.557" y1="1.068" y2="8.939"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="66.367" x2="55.557" y1="4.374" y2="8.939"/>
                        
                <line x1="67.316" x2="58.138" y1="6.62" y2="10.496"/>
                      
                <line class="hi" stroke="#3050F8" x1="66.367" x2="60.962" y1="4.374" y2="6.656499999999999"/>
                <line class="hi" stroke="#3050F8" x1="67.316" x2="62.727000000000004" y1="6.62" y2="8.558"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="72.455" x2="76.717" y1="6.31" y2="11.232"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="71.695" x2="77.371" y1="27.578" y2="18.181"/>
                        
                <line x1="70.524" x2="75.284" y1="24.801" y2="16.92"/>
                      
                <line class="hi" stroke="#3050F8" x1="77.371" x2="74.53299999999999" y1="18.181" y2="22.8795"/>
                <line class="hi" stroke="#3050F8" x1="75.284" x2="72.904" y1="16.92" y2="20.860500000000002"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="71.695" x2="60.166" y1="27.578" y2="24.893"/>
                  
            <line class="bond" id="mol1bnd6" x1="55.557" x2="56.531" y1="8.939" y2="20.279"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.83" x2="44.975" y1="26.559" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.975" x2="44.975" y1="48.914" y2="33.674"/>
                        
                <line x1="42.536" x2="42.536" y1="47.505" y2="35.082"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="44.975" x2="31.767" y1="48.914" y2="56.534"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="18.559" x2="31.767" y1="48.914" y2="56.534"/>
                        
                <line x1="20.997" x2="31.767" y1="47.505" y2="53.719"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="18.559" x2="18.559" y1="48.914" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="31.767" x2="18.559" y1="26.054" y2="33.674"/>
                        
                <line x1="31.767" x2="20.997" y1="28.869" y2="35.082"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="44.975" x2="31.767" y1="33.674" y2="26.054"/>
                  
            <line class="bond" id="mol1bnd14" x1="18.559" x2="6.875" y1="48.914" y2="55.662"/>
                  
            <line class="bond" id="mol1bnd15" x1="44.975" x2="56.862" y1="48.914" y2="58.464"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="56.862" x2="68.391" y1="58.464" y2="55.779"/>
                        
                <line x1="57.464" x2="67.838" y1="55.82" y2="53.404"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="55.779" y2="57.1215"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="53.404" y2="54.612"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="73.482" x2="78.299" y1="51.298" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd18" x1="71.695" x2="78.299" y1="27.578" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd19" x1="56.862" x2="53.476" y1="58.464" y2="73.323"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="53.476" x2="38.87" y1="73.323" y2="77.83"/>
                        
                <line x1="52.851" x2="40.948" y1="76.068" y2="79.741"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="38.87" x2="35.619" y1="77.83" y2="92.72"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="35.619" x2="46.756" y1="92.72" y2="103.158"/>
                        
                <line x1="38.297" x2="47.383" y1="91.887" y2="100.404"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="46.756" x2="61.384" y1="103.158" y2="98.552"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="61.384" x2="64.634" y1="98.552" y2="83.662"/>
                        
                <line x1="59.304" x2="61.955" y1="96.651" y2="84.504"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="53.476" x2="64.634" y1="73.323" y2="83.662"/>
                  
            <line class="bond" id="mol1bnd26" x1="64.634" x2="75.987" y1="83.662" y2="80.097"/>
                  
            <path class="atom" d="M71.538 5.459h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M81.515 16.982h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M58.802 26.573h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M2.906 54.72q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .91 .417 1.446q.422 .53 1.268 .53q.321 -.0 .607 -.054q.291 -.059 .565 -.142v.535q-.274 .102 -.565 .149q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.745 .268 -1.31q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.226 -.101 -.506 -.185q-.274 -.083 -.607 -.083zM5.662 59.143h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M73.636 57.459h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm15" stroke="none"/>
                  
            <path class="atom" d="M79.668 77.12q-.785 -.0 -1.238 .53q-.452 .524 -.452 1.446q-.0 .911 .417 1.447q.422 .53 1.268 .53q.321 -.0 .607 -.054q.291 -.059 .565 -.143v.536q-.274 .101 -.565 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q-.0 -.744 .268 -1.309q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.227 -.101 -.506 -.185q-.274 -.083 -.608 -.083zM82.425 81.543h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm23" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="72.455" x2="74.586" y1="6.31" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="76.717" x2="74.586" y1="11.232" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="60.166" x2="65.9305" y1="24.893" y2="26.235500000000002"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="56.531" x2="56.044" y1="20.279" y2="14.609"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="53.83" x2="49.4025" y1="26.559" y2="30.116500000000002"/>
            <line class="hi" id="mol1bnd14" stroke="#1FF01F" x1="6.875" x2="12.717" y1="55.662" y2="52.288"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="73.482" x2="75.8905" y1="51.298" y2="46.296"/>
            <line class="hi" id="mol1bnd26" stroke="#1FF01F" x1="75.987" x2="70.31049999999999" y1="80.097" y2="81.87950000000001"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Adjuvants, Anesthesia; GABA Modulators; Sedatives, Nonbarbiturate","Title":"Triazolam","UNII":"1HM943223R","Wikidata":"Q412143","Wikipedia":"Triazolam","XLogP":2.4}